Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Health Economics Review
Published in: Health Economics Review 1/2023

Open Access 01-12-2023 | Valsartan | Research

Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran

Authors: Ramin Ravangard, Farideh Sadat Jalali, Marjan Hajahmadi, Abdosaleh Jafari

Published in: Health Economics Review | Issue 1/2023

Login to get access

Abstract

Background

Today, heart failure is one of the leading causes of death and disability in most developed and developing countries. By 2030, more than 23.3 million people are projected to die of cardiovascular diseases each year, and the prevalence of heart failure is expected to increase by 25%. One of the preventive interventions is pharmacological interventions which can be used to reduce the complications of cardiovascular diseases such as heart failure. One of the most important pharmacological interventions in patients with heart failure is the use of antihypertensive drugs such as candesartan, enalapril, and valsartan. This study aimed to compare the cost-utility of candesartan, enalapril, and valsartan in patients with heart failure using the Markov model in Iran in 2020.

Methods

In the present study, a four-state Markov model was designed to compare the cost-utility of candesartan, enalapril, and valsartan for a hypothetical cohort of 10,000 heart failure patients older than 24 years. The payers’ perspective was used to calculate the costs. The Markov states included outpatients with heart failure, patients with heart failure admitted to general hospital wards, patients with heart failure admitted to the intensive care units (ICUs), and death. The effectiveness measure in this study was the quality-adjusted life years (QALYs). The one-way and probabilistic sensitivity analyses were used to determine the robustness of the results. The TreeAge Pro 2011 software was used for data analysis.

Results

The results showed that the average expected costs and QALYs were 119645.45 USD and 16.15 for valsartan, 113,019.68 USD and 15.16 for enalapril, and 113,093.37 USD and 15.06 for candesartan, respectively. Candesartan was recognized as the dominated option. Because the calculated incremental cost-effectiveness ratio (ICER) value (6,692.69 USD) was less than the threshold value (7,256 USD), valsartan was cost-effective compared to enalapril. The results of the cost-effectiveness acceptability curve showed that at the threshold of 7,256 USD, valsartan had a 60% chance of being cost-effective compared to enalapril. The results of one-way and probabilistic sensitivity analyses confirmed the robustness of the results. Moreover, the results showed that ICU (1,112 USD) had the highest cost among cost items.

Conclusion

According to the results, it is recommended that health policymakers consider the use of valsartan by cardiologists when designing clinical guidelines for the treatment of patients with heart failure.
Appendix
Available only for authorised users
Literature
1.
Heidenreich PATJ, Khavjou OA, Butler J, Dracup K, Ezekowitz MDFE, Hong Y, Johnston SC, Khera A. Forecasting the future of cardiovascular disease in the United States: a policy statement. Am Heart Association Circulation. 2011;8:933–44.
2.
Vahdatimanesh Z, Zendehdel K, Kbari Sari AA, Farhan F, Nahvijou A, Delavari A, Daroudi R. Economic Burden of Colorectal Cancer in Iran in 2012. Med J Islamic Repub Iran. 2017;31:768–73.
3.
Zeighami Mohammadi S, Farmani P, Shakoor M, Fahidy F, Fallah Taherpazir E, Mohseni B. Correlation between type D personality and quality of life in heart failure patients. Int J Biomed Public Health. 2018;1:76–81.
4.
Baert A, De Smedt D, De Sutter J, De Bacquer D, Puddu PE, Clays E, Pardaens S. Factors associated with health-related quality of life in stable ambulatory congestive heart failure patients: systematic review. Eur J Prev Cardiol. 2018;25:472–81.PubMed
5.
Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S. Executive summary: heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129:399–410.PubMed
6.
Sadoughi F, Moulaei2 K, Ahmadi Farsani M, Hadian M. Effciency and Effectiveness of Telemedicine in the management and monitoring of Heart Disease: Systematized Review. Iran J Med Sci. 2019;4:51–9.
7.
Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020;22:1342–56.PubMed
8.
Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR. Heart disease and stroke Statistics-2019 update a report from the American Heart Association. Circulation. 2019;139:56–28.
9.
Störk S, Handrock R, Jacob J, Walker J, Calado F, Lahoz R, Hupfer S, Klebs S. Epidemiology of heart failure in Germany: a retrospective database study. Clin Res Cardiol. 2017;106:913–22.PubMedPubMedCentral
10.
Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JG, McMurray JJ. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. The Lancet. 2018;391:572–80.
11.
Smeets M, Vaes B, Mamouris P, Van Den Akker M, Van Pottelbergh G, Goderis G, Janssens S, Aertgeerts B, Henrard S. Burden of heart failure in flemish general practices: a registry-based study in the Intego database. BMJ open. 2019;9:25–33.
12.
13.
Savarese G, Becher PM, Lund LH, Seferovic P, Rosano G, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Res 2022.
14.
Forouzanfar MH, Sepanlou SG, Shahraz S, Dicker D, Naghavi P, Pourmalek F, Mokdad A, Lozano R, Vos T, Asadi-Lari M. Evaluating causes of death and morbidity in Iran, global burden of diseases, injuries, and risk factors study 2010. Arch Iran Med. 2014;17:1–17.
15.
Harkness K, Spaling MA, Currie K, Strachan PH, Clark AM. A systematic review of patient heart failure self-care strategies. J Cardiovasc Nurs. 2015;30:121–35.PubMed
16.
Wu J-R, Holmes GM, DeWalt DA, Macabasco-O’Connell A, Bibbins-Domingo K, Ruo B, Baker DW, Schillinger D, Weinberger M, Broucksou KA. Low literacy is associated with increased risk of hospitalization and death among individuals with heart failure. J Gen Intern Med. 2013;28:1174–80.PubMedPubMedCentral
17.
Sarrafzadegan N, Mohammmadifard N. Cardiovascular disease in Iran in the last 40 years: prevalence, mortality, morbidity, challenges and strategies for cardiovascular prevention. Arch Iran Med. 2019;22:204–10.PubMed
18.
Darba S, Safaei N, Mahboub–Ahari A, Nosratnejad S, Alizadeh G, Ameri H, Yousefi M. Direct and indirect costs Associated with Coronary Artery (Heart) Disease in Tabriz, Iran. Risk Manage Healthc Policy. 2020;13:969.
19.
Khorrami ER, Zakeri MM. Factors affecting heart failure outcomes: a review article. Cardiovasc Nurs J. 2018;7:58–67.
20.
Mansouriyeh N, PoursharifIi H, Taban Sadeghi M, Seirafi M. The relationship between socioeconomic status and self-care in patients with heart failure: the role of illness related worries mediator. J Nurse Physician Within War. 2018;7:5–12.
21.
Ramos IC, Versteegh MM, de Boer RA, Koenders JM, Linssen GC, Meeder JG. Rutten-van Mölken MPJViH: cost effectiveness of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan for patients with chronic heart failure and reduced ejection fraction in the Netherlands: a country adaptation analysis under the former and current dutch pharmacoeconomic guidelines. 2017, 20:1260–9.
22.
Ramos IC, Versteegh MM, de Boer RA, Koenders JM, Linssen GC, Meeder JG, Rutten-van Mölken MP. Cost effectiveness of the angiotensin receptor neprilysin inhibitor sacubitril/valsartan for patients with chronic heart failure and reduced ejection fraction in the Netherlands: a country adaptation analysis under the former and current dutch pharmacoeconomic guidelines. Value in Health. 2017;20:1260–9.PubMed
23.
Sarrafzadegan N, Rabiei K, Sadeghi M, Gharipour M, Hosieni M, Zolfaghari B, Cheraghi M, Feizbakhsh A, Mostofi A, Zarfeshani S. The outcome of secondary prevention interventions in a community based interventional program: Isfahan Healthy Heart program. Yafte. 2012;14:55–67.
24.
Faruqi A, Jain A. Enalapril. StatPearls [Internet]. StatPearls Publishing; 2021.
25.
Dargad RR, Prajapati MR, Dargad RR, Parekh JD. Sacubitril/valsartan: a novel angiotensin receptor-neprilysin inhibitor. Indian Heart J. 2018;70:102–S110.
26.
Iraji F, Garekyaraghi M, Ahmadi Z, Nilforoushzadeh MA, Faghihi G. Skin reaction with lozartan and enalapril drugs in patients in 2008. J Isfahan Med School. 2012;29:3040–5.
27.
Granström O, Levin L-Ã, Henriksson M. Cost-effectiveness of candesartan versus losartan in the primary preventive treatment of hypertension. ClinicoEconomics and Outcomes Research. 2012;4:313–22.PubMedPubMedCentral
28.
29.
30.
Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the heart failure society of America. J Am Coll Cardiol. 2017;70:776–803.PubMed
31.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, Burri H, Butler J, Čelutkienė J, Chioncel O. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the heart failure Association (HFA) of the ESC. Eur Heart J. 2021;42:3599–726.PubMed
32.
Krittayaphong R, Permsuwan U. Cost-effectiveness analysis of sacubitril-valsartan compared with enalapril in patients with heart failure with reduced ejection fraction in Thailand. Am J Cardiovasc Drugs. 2018;18:405–13.PubMed
33.
Turner HC, Archer RA, Downey LE, Isaranuwatchai W, Chalkidou K, Jit M, Teerawattananon Y. An introduction to the main types of economic evaluations used for informing priority setting and resource allocation in healthcare: key features, uses, and limitations. Front Public Health. 2021;9:722927.PubMedPubMedCentral
34.
Ademi Z, Pfeil AM, Hancock E, Trueman D, Haroun RH, Deschaseaux C, Schwenkglenks M. Cost-effectiveness of sacubitril/valsartan in chronic heart-failure patients with reduced ejection fraction. Swiss Med Wkly. 2017;39:147–72.
35.
Gaziano TA, Fonarow GC, Claggett B, Chan WW, Deschaseaux-Voinet C, Turner SJ, Rouleau JL, Zile MR, McMurray JJ, Solomon SD. Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction. J Am Med Association Cardiol. 2016;1:666–72.
36.
Mansouri K, Hasavari F, Sadeghi Sabet M, Kazemnejad-Leili E, Gholipour M. Self-Care Status and its related factors in patients with heart failure. J Health Care. 2018;19:232–41.
37.
van der Pol S, Degener F, Postma MJ, Vemer P. An economic evaluation of sacubitril/valsartan for heart failure patients in the Netherlands. Value in Health. 2017;20:388–96.PubMed
38.
van der Pol S, de Jong LA, Vemer P, Jansen DE, Postma MJ. Cost-effectiveness of sacubitril/valsartan in Germany: an application of the efficiency frontier. Value in Health. 2019;22:1119–27.PubMed
39.
Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J. Loder EJIjotaihc: Consolidated health economic evaluation reporting standards (CHEERS) statement. 2013, 29:117–122.
40.
Rezapour A, Palmer AJ, Alipour V, Hajahmadi M, Jafari AJCE, Allocation R. The cost-effectiveness of B-type natriuretic peptide-guided care in compared to standard clinical assessment in outpatients with heart failure in Tehran, Iran. 2021, 19:1–9.
41.
Hu L, Li L, Ji J, Sanderson M. Identifying and understanding determinants of high healthcare costs for breast cancer: a quantile regression machine learning approach. BMC Health Serv Res. 2020;20:1–10.
42.
McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.PubMed
43.
Givi M, Shafie D, Garakyaraghi M, Yadegarfar G, Roohafza HR, Ahmadi SA, Nouri F, Sarrafzadegan NJGMJ. Patients characteristics and preliminary outcomes of heart failure registry in a middle-income country: persian registry of cardiovascular disease/heart failure (PROVE/HF). 2018, 7:e1026.
44.
45.
Stintzing S, van Oostrum I, Pescott CP, Ronga P, Heeg B, Heinemann V. Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + Bevacizumab in the first-line treatment of RAS Wild-type metastatic colorectal Cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study. J Med Econ. 2020;23:448–55.PubMed
46.
Daneshmand A, Jahangard E, Abdollah-Milani M. A time preference measure of the social discount rate for Iran. J Economic Struct. 2018;7:29–35.
47.
Haacker M, Hallett TB, Atun R. On discount rates for economic evaluations in global health. Health Policy Plann. 2020;35:107–14.
48.
Ewara EM, Zaric GS, Welch S, Sarma S. Cost-effectiveness of First-Line treatments for patients with KRAS Wild-Type Metastatic Colorectal Cancer. Curr Oncol. 2014;21:541–50.
49.
Newcombe J, Hawkins C, Henderson C, Patel H, Woodroofe M, Hayes G, Cuzner M, MacManus D, BOULAY ED, McDonald W. Histopathology of multiple sclerosis lesions detected by magnetic resonance imaging in unfixed postmortem central nervous system tissue. Brain. 1991;114:1013–23.PubMed
50.
Barton GR, Briggs AH, Fenwick EA. Optimal cost-effectiveness decisions: the role of the cost‐effectiveness acceptability curve (CEAC), the cost‐effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Value in Health. 2008;11:886–97.PubMed
51.
McMurray J. Angiotensin–neprilysin inhibition versus Enalapril in Heart failure. N Engl J Med. 2014;371:993–1004.PubMed
52.
Corrao G, Ghirardi A, Ibrahim B, Merlino L, Maggioni AP. Short-and long-term mortality and hospital readmissions among patients with new hospitalization for heart failure: a population-based investigation from Italy. Int J Cardiol. 2015;181:81–7.PubMed
53.
Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP, Committee ASA. Investigators: characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart failure National Registry (ADHERE). Am Heart J. 2005;149:209–16.PubMed
54.
Packer M, McMurray JJ, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131:54–61.PubMed
55.
Desai AS, Claggett BL, Packer M, Zile MR, Rouleau JL, Swedberg K, Shi V, Lefkowitz M, Starling R, Teerlink J. Influence of sacubitril/valsartan (LCZ696) on 30-day readmission after heart failure hospitalization. J Am Coll Cardiol. 2016;68:241–8.PubMed
56.
Jafari A, Rezapour A, Hajahmadi M. Cost-effectiveness of B-type natriuretic peptide-guided care in patients with heart failure: a systematic review. Heart Fail Rev. 2018;23:693–700.PubMed
57.
Gordin JS, Fonarow GC. New medications for heart failure. Trends in Cardiovasc Med. 2016;26:485–92.
58.
59.
Jabbari A, Jafari A, Hadian M, Ghasemi M. Model-based cost-effectiveness analysis of atorvastatin drugs for prevention of cardiovascular diseases in Iran. Int J Prev Med. 2020;11:57.PubMedPubMedCentral
60.
Gaziano TA, Fonarow GC, Velazquez EJ, Morrow DA, Braunwald E, Solomon SD. Cost-effectiveness of sacubitril-valsartan in hospitalized patients who have heart failure with reduced ejection fraction. JAMA Cardiol. 2020;5:1236–44.PubMedPubMedCentral
61.
Borges M, Afonso-Silva M, Laires PA, Gouveia M, Alarcão J, Ascenção R, Costa J. Cost-effectiveness of sacubitril/valsartan for the treatment of patients with heart failure with reduced ejection fraction in Portugal. Expert Rev PharmacoEcon Outcomes Res. 2020;20:199–205.PubMed
62.
Pradelli L, Iannazzo S, Zaniolo O. The cost effectiveness and cost utility of Valsartan in Chronic Heart failure therapy in Italy. Am J Cardiovasc Drugs. 2009;9:383–92.PubMed
63.
McMurray JJ, Trueman D, Hancock E, Cowie MR, Briggs A, Taylor M, Mumby-Croft J, Woodcock F, Lacey M, Haroun R. Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart. 2018;104:1006–13.PubMed
64.
King JB, Shah RU, Bress AP, Nelson RE, Bellows BK. Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC: Heart Failure. 2016;4:392–402.PubMed
65.
Liang L, Bin-Chia Wu D, Aziz MIA, Wong R, Sim D, Leong KTG, Wei YQ, Tan D, Ng K. Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction. J Med Econ. 2018;21:174–81.PubMed
Metadata
Title
Cost-utility analysis of valsartan, enalapril, and candesartan in patients with heart failure in Iran
Authors
Ramin Ravangard
Farideh Sadat Jalali
Marjan Hajahmadi
Abdosaleh Jafari
Publication date
01-12-2023
Publisher
Springer Berlin Heidelberg
Published in
Health Economics Review / Issue 1/2023
Electronic ISSN: 2191-1991
DOI
https://doi.org/10.1186/s13561-023-00457-4

Other articles of this Issue 1/2023

Health Economics Review 1/2023 Go to the issue

Research

The impact of health insurance enrollment on health outcomes in Kenya

Research

The role of risk preferences: voluntary health insurance in rural Tanzania

Research

The impact of medical insurance on family financial support: evidence from CHARLS in China

Research

Sustaining medical research – the role of trust and control

Research

Health outcome convergence in Africa: the roles of immunization and public health spending

Research

Transcatheter aortic valve implantation against conventional aortic valve replacement surgery in high-risk patients with aortic stenosis; a cost-effectiveness analysis